Given that PP2A is rarely mutated or lost in KRAS-mutant NSCLC, we sought to investigate alterations in the posttranslational modifications of PP2A upon RAS/MAPKi using KRASG12C and MEK1/2 inhibitors. This evidence concerns the gene KRAS and non-small cell lung carcinoma.